Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Jun;122(3):245-257.
doi: 10.1016/j.pain.2006.01.037. Epub 2006 Mar 13.

Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction

Sarah J L Flatters  1 , Gary J Bennett
Affiliations

Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction

Sarah J L Flatters et al. Pain. 2006 Jun.

Abstract

Paclitaxel chemotherapy frequently induces neuropathic pain during and often persisting after therapy. The mechanisms responsible for this pain are unknown. Using a rat model of paclitaxel-induced painful peripheral neuropathy, we have performed studies to search for peripheral nerve pathology. Paclitaxel-induced mechano-allodynia and mechano-hyperalgesia were evident after a short delay, peaked at day 27 and finally resolved on day 155. Paclitaxel- and vehicle-treated rats were perfused on days 7, 27 and 160. Portions of saphenous nerves were processed for electron microscopy. There was no evidence of paclitaxel-induced degeneration or regeneration as myelin structure was normal and the number/density of myelinated axons and C-fibres was unaltered by paclitaxel treatment at any time point. In addition, the prevalence of ATF3-positive dorsal root ganglia cells was normal in paclitaxel-treated animals. With one exception, at day 160 in myelinated axons, total microtubule densities were also unaffected by paclitaxel both in C-fibres and myelinated axons. C-fibres were significantly swollen following paclitaxel at days 7 and 27 compared to vehicle. The most striking finding was significant increases in the prevalence of atypical (swollen and vacuolated) mitochondria in both C-fibres (1.6- to 2.3-fold) and myelinated axons (2.4- to 2.6-fold) of paclitaxel-treated nerves at days 7 and 27. Comparable to the pain behaviour, these mitochondrial changes had resolved by day 160. Our data do not support a causal role for axonal degeneration or dysfunction of axonal microtubules in paclitaxel-induced pain. Instead, our data suggest that a paclitaxel-induced abnormality in axonal mitochondria of sensory nerves contributes to paclitaxel-induced pain.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Behavioural time-course of mechano-allodynia and mechano-hyperalgesia induced by paclitaxel treatment. Graph shows the mean ± SEM of the response frequency to mechanical stimulation by (A) von Frey 4 g, (B) von Frey 8 g and (C) von Frey 15 g. n = 8–14 for vehicle treatment, n = 10–17 for paclitaxel treatment. *p < 0.05, #p < 0.01, one-way repeated-measures ANOVA with Dunnett’s post hoc analysis compared to baseline (BL).
Fig. 2
Fig. 2
Saphenous nerve sections from (A) vehicle-treated and (B) paclitaxel-treated rats at day 27 post-treatment initiation, i.e., at the time of peak of paclitaxel-induced pain behaviour. Examination at this magnification (725×) shows that the overall morphology of peripheral sensory nerves is unaltered by paclitaxel treatment. Note: the fine black lines seen in (A) are small folds in the section. Graphs show the mean ± SEM of the number of (C) myelinated axons and (D) C-fibres in complete saphenous nerve sections of vehicle-treated and paclitaxel-treated rats, n = 3 per group (C) and n = 2 per group (D). There is no significant difference in the number of myelinated axons or C-fibres following paclitaxel treatment, at any time point, compared to vehicle treatment (two-tailed unpaired t-tests, Welch correction applied as appropriate).
Fig. 3
Fig. 3
ATF3-immuno-reactivity in nuclei of L4/5 DRG cells. (A) Three days following complete sciatic nerve transection, the majority of cells are ATF3-positive. (B) Day 27 post-paclitaxel initiation, virtually no ATF3-positive cells. Micrographs taken at 10× magnification. Scale bar, 100 μm.
Fig. 4
Fig. 4
Effect of paclitaxel on cross-sectional area of C-fibres. Graph shows the mean ± SEM of the C-fibre area in vehicle-treated and paclitaxel-treated nerves at days 7, 27 and 160 post-initiation of treatment. At each time point, 120 C-fibres were measured from two vehicle-treated rats and 180 C-fibres from three paclitaxel-treated rats. Vehicle n = 120, paclitaxel n = 180: #p < 0.01, two-tailed unpaired t-tests, Welch correction applied as appropriate.
Fig. 5
Fig. 5
Effect of paclitaxel on total microtubule densities in myelinated axons and C-fibres. Graphs show the mean ± SEM of the total microtubule density in (A) myelinated axons and (B) C-fibres of vehicle-treated and paclitaxel-treated nerves at days 7, 27 and 160 postinitiation of treatment. At each time point, microtubules were counted in 120 myelinated axons/C-fibres randomly sampled from two vehicle-treated rats and 180 myelinated axons/C-fibres randomly sampled from three paclitaxel-treated rats. Vehicle n = 120, paclitaxel n = 180: #p < 0.01, two-tailed unpaired t-tests.
Fig. 6
Fig. 6
Circular and oblique microtubule profiles in a myelinated axon. Axoplasm of a myelinated axon in the saphenous nerve from a paclitaxel-treated rat at day 27 post-treatment initiation (44,400×). Circular (arrowheads) and oblique (arrows) microtubules. Note that circular microtubules occur with a much greater frequency than oblique microtubules.
Fig. 7
Fig. 7
Effect of paclitaxel on circular and oblique microtubule populations in myelinated axons. Graphs show the mean ± SEM of the density of (A) circular microtubule profiles and (B) oblique microtubule profiles in myelinated axons of vehicle-treated and paclitaxel-treated nerves at days 7, 27 and 160 post-initiation of treatment. At each time point, circular and oblique microtubules were counted in 120 myelinated axons randomly sampled from two vehicle-treated rats and 180 myelinated axons randomly sampled from three paclitaxel-treated rats. Vehicle n = 120, paclitaxel n = 180: #p < 0.01, two-tailed unpaired t-tests, Welch correction applied as appropriate. Note: marked 16-fold change in y-axis range in (B) compared to (A).
Fig. 8
Fig. 8
Effect of paclitaxel on microtubule populations in C-fibres. Graphs show the mean ± SEM of the number of (A) total microtubules, (B) circular microtubules and (C) oblique microtubules per C-fibre in vehicle-treated and paclitaxel-treated nerves at days 7, 27 and 160 post-initiation of treatment. At each time point, microtubules were counted and classified in 120 C-fibres randomly sampled from two vehicle-treated rats and 180 C-fibres randomly sampled from three paclitaxel-treated rats. Vehicle n = 120, paclitaxel n = 180: *p < 0.05, two-tailed unpaired t-tests, Welch correction applied as appropriate. Note: the marked 20-fold change in y-axis range in (C) compared to (A) and (B).
Fig. 9
Fig. 9
Atypical and normal mitochondria in C-fibres of the saphenous nerve of paclitaxel-treated rats. Normal mitochondria (arrowheads) and atypical (swollen and vacuolated) mitochondria (arrows). (A) Remak bundle with Schwann cell nucleus from a paclitaxel-treated rat at day 27 post-treatment initiation. (B, C) C-fibres from nucleated Remak bundle shown in (A) of paclitaxel-treated rat at day 27 post-treatment initiation. (D) C-fibres from a paclitaxel-treated rat at day 7 post-treatment initiation. Magnifications: (A) 13,800×, (B–D) 44,400×.
Fig. 10
Fig. 10
Atypical and normal mitochondria in myelinated axons of the saphenous nerve of paclitaxel-treated rats. Normal mitochondria (arrowheads) and atypical (swollen and vacuolated) mitochondria (arrows). (A) Small, thinly myelinated Aδ-fibre and (B) large myelinated Aβ-fibre of a paclitaxel-treated rat at day 7 post-treatment initiation. (C) Small, thinly myelinated Aδ-fibre and (D) large myelinated Aβ-fibre of a paclitaxel-treated rat at day 27 post-treatment initiation. Magnification: (A–D) 44,400×.
Fig. 11
Fig. 11
Effect of paclitaxel on the prevalence of atypical mitochondria in C-fibres and myelinated axons. Graphs show the mean ± SEM of the percentage of (A) C-fibres and (B) myelinated axons that contained atypical mitochondria in vehicle-treated and paclitaxel-treated nerves at days 7, 27 and 160 post-initiation of treatment. Sixty myelinated axons/C-fibres were randomly sampled per animal and the number of myelinated axons/C-fibres that contained atypical mitochondria counted and expressed as a percentage of the total C-fibres/myelinated axons sampled. At each time point, n = 2 for vehicle treatment and n = 3 for paclitaxel treatment. #p < 0.01, Fisher’s exact test.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Andre N, Braguer D, Brasseur G, Goncalves A, Lemesle-Meunier D, Guise S, et al. Paclitaxel induces release of cytochrome c from mitochondria isolated from human neuroblastoma cells. Cancer Res. 2000;60:5349–53. - PubMed
    1. Authier N, Gillet JP, Fialip J, Eschalier A, Coudore F. Description of a short-term Taxol-induced nociceptive neuropathy in rats. Brain Res. 2000;887:239–49. - PubMed
    1. Brewer PA, Lynch K. Stimulation-associated changes in frog neuro-muscular junctions. A quantitative ultrastructural comparison of rapid-frozen, chemically fixed nerve terminals. Neuroscience. 1986;17:881–95. - PubMed
    1. Campana WM, Eskeland N, Calcutt NA, Misasi R, Myers RR, O’Brien JS. Prosaptide prevents paclitaxel neurotoxicity. Neurotoxicology. 1998;19:237–44. - PubMed
    1. Carre M, Andre N, Carles G, Borghi H, Brichese L, Briand C, et al. Tubulin is an inherent component of mitochondrial membranes that interacts with the voltage-dependent anion channel. J Biol Chem. 2002;277:33664–9. - PubMed

Publication types

MeSH terms

Substances